Affiliation:
1. Federal University of Ceará, Brazil
Abstract
Hydroxyurea (HU) is the most important advance in the treatment of sickle cell anaemia (SCA) for preventing complications and improving quality of life for patients. However, some aspects of treatment with HU remain unclear, including their effect on and potential toxicity to other blood cells such as neutrophils. This study used the measurement of Lactate Dehydrogenase (LDH) and Methyl ThiazolTetrazolium (MTT) and the comet assay to investigate the cytotoxicity and damage index (DI) of the DNA in the neutrophils of patients with SCA using HU.In the LDH and MTT assays, a cytoprotective effect was observed in the group of patients treated, as well as an absence of toxicity. When compared to patients without the treatment, the SS group (n=20, 13 women and 07 men, aged 18-69 years), and the group of healthy individuals (AA) used as a control group (n=52, 28 women and 24 men, aged 19-60 years), The SSHU group (n=21, 11 women and 10 men, aged 19-63 years) showed a significant reduction (p<0.001) in LDH activity and an increase in the percentage of viable cells by the MTT (p<0.001). However, the SSHU group presented significantly higher DI values (49.57±6.0 U/A) when compared to the AA group (7.43 ± 0,94U/A) and the SS group (22.73 ±5.58 U/A) (p<0.0001), especially when treated for longer periods (>20 months), demonstrating that despite the cytoprotective effects in terms of cell viability, the use of HU can induce DNA damage in neutrophils.
Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference55 articles.
1. Further studies in the assessment of toxic actions;ALIVERTI V.,1980
2. More definitions in sickle cell disease: steady state v base line data;BALLAS S.K.;Am. J. Hematol.,2012
3. Portaria SAS/MS Nº 872, de 06 de novembro de 2002, publicada no Diário Oficial da União, de 8 de novembro de 2002, seção 1, página 169 - Aprova o protocolo clínico e diretrizes terapêuticas /Doença Falciforme/ Hidroxiuréia,2002
4. National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease;BRAWLEY O.W.;Ann. Intern. Med.,2008
5. Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme;CANÇADO R.D.;Rev. Bras. Hematol. Hemoter.,2009
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献